The framework has received support from healthcare policy specialists and stakeholders within the medtech sector, who believe it could help NHS purchasing decisions better account for the long-term benefits and impact of healthcare technologies. Chris Whitehouse, Director of Health and MedTech Policy at Whitehouse Communications, which advises medical device suppliers, said: “For many years, procurement decisions across parts of the NHS have too often been driven primarily by upfront cost.” While the framework establishes a new direction for procurement practices, industry observers note that its success will depend on how effectively it is adopted across NHS organisations and integrated into existing decision-making processes.

Attention will also be required in areas such as procurement culture and stakeholder engagement to ensure the intended benefits are realised. Whitehouse emphasised that policy changes alone would not be enough to transform purchasing practices, stating: “Changing procurement frameworks on paper is relatively straightforward. Changing behaviours and cultures that have developed over many years is much harder,” he said. A central feature of the framework is the earlier involvement of clinicians in procurement discussions, recognising their insight into how technologies perform in real-world healthcare environments and how they influence patient care.

The framework further underlines the importance of patient experience as a measure of value. NHS organisations are encouraged to consider how technologies affect factors such as independence, dignity and quality of life when assessing procurement options. Through this outcomes-focused model, value-based procurement for Medical Device assessment aims to support more informed purchasing decisions while aligning procurement practices with broader healthcare objectives across the NHS.

The decision follows findings that equated the daily time savings to roughly five weeks per staff member each year. Health Innovation and Safety Minister Preet Kaur Gill said: “Every day, doctors, nurses and other healthcare professionals spend valuable time on administrative tasks that take them away from patients.” She added: “By rolling out Microsoft Copilot across the NHS, we can reduce that burden, free up clinicians’ time and help staff focus on what they do best, caring for patients.” Rob Thompson, Chief Digital, Data and Technology Officer at NHS England, said: “The potential to save clinical staff nearly a day’s worth of admin time every fortnight could be a gamechanger for patients.” He added: “We’re making sure every pound is spent on cutting waiting times and boosting care through the Plan for Change and 10 Year Health Plan.”

The deployment will support a range of operational and administrative functions across NHS England. Ward clerks will use the technology for patient discharge processes, rota planning and bed management, while medical secretaries will apply it to meeting documentation and template creation. Administrative teams in HR, finance and procurement will also use the platform, and management groups will employ it to prepare board papers and briefings. NHS England will additionally gain access to Copilot Studio, enabling individual NHS Trusts to build customized AI agents for workflow automation, including support for helpdesk operations, complaints handling, freedom of information requests and financial processing. Agent 365 will provide governance controls to ensure those agents comply with organizational security requirements.

Microsoft UK and Ireland CEO Darren Hardman said: “By rolling out Microsoft 365 Copilot at scale, NHS teams can cut through everyday admin and spend more time where it matters most.” He added: “Bringing AI safely into the flow of healthcare will help ease pressures, improve productivity, and support better decision-making across the health service.” NHS England serves approximately 56 million people and employs around 1.4 million staff, making this one of the largest enterprise AI deployments undertaken by a healthcare organization. The structured onboarding programme will run for 12 months and is intended to support adoption across the health system while providing a large-scale example of AI implementation in public healthcare.

For decades, patient data across the NHS has remained siloed across dozens of disconnected systems GP records, hospital trusts, mental health providers, and community care teams each holding separate, often incompatible records. The result has been persistent gaps in care, repeated diagnostic tests, and clinical decisions made without full visibility of a patient’s history.

The NHS single patient record initiative directly addresses this fragmentation. Under the proposed model, authorised healthcare professionals would be able to access a comprehensive, real-time view of a patient’s medical history, medications, diagnoses, allergies, and previous care interactions regardless of which part of the system that patient has previously engaged with.

The consolidated record is intended to bring together information currently scattered across primary, secondary, and community care settings. This includes GP records, hospital discharge summaries, diagnostic results, prescribed medications, and relevant social care data. Clinicians treating a patient in an emergency, for example, would no longer need to rely on incomplete information or wait for records to be manually transferred.

The NHS federated data platform is expected to play a key role in enabling this infrastructure. Rather than creating a single centralised database, the federated model allows data to remain within local systems while still being accessible in a joined-up way addressing both technical and governance concerns around data centralisation.

A key aspect of the plans involves giving patients greater agency over their own health information. The proposals include mechanisms for individuals to view their own records and, where appropriate, control how their data is shared across care settings. This reflects growing expectations around transparency and data rights within the public sector.

Data security and consent frameworks are central to the implementation design. NHS England has indicated that robust safeguards would govern who can access records and under what circumstances, with strict audit trails and access controls built into the system architecture.

From a healthcare operations standpoint, a functioning single patient record system carries substantial implications for NHS efficiency. Duplication of tests and procedures a known cost driver within the health service could be reduced significantly if clinicians have immediate access to prior results. Clinical handovers between teams and care settings, frequently a point of risk in patient safety terms, would also benefit from more complete and consistent information sharing.

The NHS digital transformation agenda has placed data interoperability at its core, and the single patient record represents one of the most tangible expressions of that direction. Healthcare modernisation at this scale requires not only technological investment but also changes in clinical workflow, staff training, and cross-organisational data agreements.

NHS England is progressing the initiative as part of its wider data and digital strategy. While a full national rollout will take time, the direction of travel is clearly set toward a more connected, data-driven health system. Integrated care systems across England are expected to play a role in the local delivery of this programme, given their remit to coordinate care across providers within defined geographies.

For healthcare industry executives and system leaders, the advancement of the NHS single patient record signals a concrete shift in how the health service intends to manage patient data moving from a fragmented, institution-by-institution model toward one built around the patient journey as a whole.

The NHS federated data platform and the broader push for healthcare modernisation reflect a system-level commitment to making patient data work harder, more safely, and more equitably across the entire care continuum.

In preparation for the rollout, the European Medicines Agency has scheduled an online information session on 24 April 2026. The session will outline key elements of the Breakthrough Devices framework and address practical considerations for stakeholders intending to participate. This step is expected to help manufacturers better understand procedural requirements and align early with regulatory expectations.

The pilot draws from the recently adopted MDCG 2025-9 guidance issued by the Medical Device Coordination Group. It also aligns with broader regulatory revisions proposed by the European Commission in December 2025, which introduced new provisions under Article 52a of the Medical Devices Regulation and Article 48a of the In Vitro Diagnostic Regulation. These updates aim to formalise a future framework for breakthrough medical technologies within the EU.

Positioned as a strategic move, the programme reinforces efforts to foster an innovation-oriented regulatory landscape across Europe. To secure a breakthrough designation, manufacturers must seek an opinion from the agency’s expert panels, with additional guidance and application templates expected ahead of the launch. The pilot also supports wider objectives tied to public health priorities, ensuring that advanced medical technologies entering the EU market continue to meet stringent quality, safety, and performance benchmarks. The Breakthrough Devices pilot is therefore expected to play a defining role in shaping future regulatory processes while strengthening confidence in high-impact innovations. The Breakthrough Devices pilot further underlines the EU’s commitment to balancing innovation with robust oversight.

With the expanded funding, AI Airlock is expected to scale its operations and support the development of sustainable regulatory pathways for AI-driven medical technologies. Delivered through collaboration between MHRA, DHSC, the NHS AI Team, and Team AB, the programme aligns with broader government strategies, including the AI Opportunities Action Plan, the Regulatory Action Plan, the 10-Year Health Plan, and the Life Sciences Sector Plan.

Commenting on the development, James Pound, Executive Director, Innovation and Compliance, said:
“Securing this multi-year funding boost marks a pivotal moment for AI Airlock and for the safe and responsible advancement of AI in healthcare.
The programme has already shown how collaborative, real-world testing can uncover regulatory challenges early and help innovators bring high-quality, safe technologies to patients faster.
This additional investment will allow us to scale up and ultimately strengthen our ability to ensure that AI-powered medical devices can reach patients safely, efficiently and with the confidence of robust regulatory oversight.”

The AI Airlock programme has evolved steadily since its pilot launch in 2024, followed by a second phase in 2025 that broadened its scope. Early findings highlighted new regulatory complexities associated with AI medical devices, particularly around risk management, accuracy, and the need to anchor model outputs in verified clinical data. It also underscored the importance of explainability in AI systems to strengthen clinician trust, alongside the necessity for continuous post-market monitoring to detect performance shifts or over-reliance.

Building on these insights, the second phase has examined specific regulatory challenges, including AI-powered diagnostic tools, pre-determined change control plans (PCCPs), and evolving use cases of AI systems. The programme has tested a wide spectrum of technologies such as large language models, voice-enabled tools, and advanced diagnostics targeting cancer and rare diseases. Outputs from this phase, including reports and case studies, are expected in Summer 2026 and will guide the design of phase three. Findings are also feeding into the National AI Commission’s work on shaping future regulatory frameworks. As AI Airlock expands, it continues to play a central role in strengthening collaboration between regulators and industry, supporting safe innovation while maintaining a robust and future-ready regulatory environment for medical devices.

Alignment Efforts to Streamline Regulatory Pathways

The collaboration focuses on improving and aligning regulatory frameworks governing medical device approvals, with both agencies exploring mutual recognition mechanisms. These mechanisms are intended to allow partial acceptance of each other’s approval processes, reducing duplication and creating more efficient pathways for manufacturers operating across both markets.

Technical discussions are underway to identify areas where regulatory convergence can be implemented without compromising safety, quality, or effectiveness standards. While alignment will increase, both regulators will retain independent authority over final approvals.

According to Lawrence Tallon, the initiative will support faster and more efficient access to advanced medical technologies, reinforcing regulatory efficiency within both healthcare ecosystems.

Policy and Trade Integration

The regulatory developments are closely tied to wider policy changes under the US-UK partnership. The US has lifted tariffs on pharmaceuticals and medical technologies imported from the UK for at least three years, reducing trade barriers and strengthening cross-border supply chains.

In parallel, the UK has outlined plans to increase pharmaceutical spending to 0.6% of GDP by 2035, signalling long-term investment in healthcare innovation. The UK’s pharmaceutical sector, which contributes £28.5 billion annually and exports nearly £21 billion in drug products, underpins this strategic direction.

Operational Impact on Healthcare Systems

From a healthcare management perspective, accelerated medical device approvals are expected to influence system-level operations:

• Shorter timelines for adoption of new diagnostic and therapeutic technologies
• Reduced regulatory complexity for cross-border technology deployment
• Greater predictability in procurement and capital planning
• Enhanced access to innovative MedTech solutions

The UK’s MedTech sector, employing over 195,000 people, stands to benefit from improved regulatory clarity and faster routes to market. Lord Vallance noted that the partnership strengthens regulatory leadership while supporting innovation uptake.

Strategic Implications for Market Access

Industry bodies including the Association of British HealthTech Industries and techUK have highlighted that regulatory alignment will provide more predictable pathways for innovators, particularly small and medium-sized enterprises.

As observed by HHM Global, the initiative reflects a broader shift toward globally connected regulatory systems, where harmonisation reduces friction in bringing new technologies to market while maintaining high safety standards.

Outlook

Ongoing technical work between the MHRA and FDA will determine the scope of future alignment and mutual recognition frameworks. Any resulting agreements will remain subject to stringent regulatory requirements, ensuring that safety and performance benchmarks are upheld.

The advancement of medical device approvals alignment marks a significant step toward more integrated healthcare systems, with implications for regulatory efficiency, procurement strategies, and innovation adoption.

Northwell, one of the largest U.S. health systems, is already working with 18 Enterprise Ireland companies, with existing engagements delivering procurement contracts, clinical pilots and trials, as well as strategic investments. Under the renewed framework, Enterprise Ireland client companies will retain direct access to Northwell’s clinical experts spanning 28 hospitals and more than 1,000 outpatient facilities. In addition, companies will be able to leverage Northwell’s innovation ecosystem and commercial infrastructure, strengthening pathways for Irish medtech expansion in a competitive global market.

The announcement aligns with Enterprise Ireland’s broader strategy to grow the Irish medtech sector internationally, following its end-of-2025 report highlighting sector expansion. Alongside this partnership, Galway-based Neurent Medical, supported by Enterprise Ireland, has also entered into an agreement with Northwell. Neurent develops the Neuromark system for treating chronic rhinitis, a device designed with a flexible shaft and atraumatic leaflets to conform to patient anatomy and reach difficult areas within the nasal cavity. The system delivers impedance-controlled, low-power radiofrequency (RF) energy to disrupt parasympathetic nerve signals, addressing symptoms such as persistent nasal congestion and rhinorrhea (runny nose). The next-generation Neuromark system received FDA clearance in June 2025, while Neurent raised $74 million (€62.5 million) in an oversubscribed Series C financing round earlier this year. With a U.S. headquarters in Braintree, Massachusetts, the company aims to scale further through this collaboration.

Enterprise Ireland also highlighted a broader wave of U.S. expansion by Irish firms, including Shorla Oncology, Fire1, Head Diagnostics and X-Bolt. These companies are strengthening their commercial, clinical and partnership footprints across the U.S., reflecting continued momentum in Ireland’s life sciences ecosystem. Government and industry leaders underscored the importance of such partnerships in enabling Irish innovation to reach global markets.

“Northwell Health has been an invaluable partner to Ireland and to Irish health tech and medtech companies. This alliance has provided Irish companies with unparalleled opportunities and privileged access to Northwell Health’s vast clinical network, serving as a critical gateway for innovative Irish companies entering and scaling within the U.S. healthcare market. Ireland’s life sciences and health tech sector is thriving, and partnerships like this are central to ensuring that innovation emerging from Ireland reaches patients in the U.S. and around the world.”

“Northwell Health is proud to sign this new strategic alliance with Enterprise Ireland and build upon years of successful collaboration. Our International Business Program has proven to be an invaluable gateway for innovative international companies seeking to enter and scale within the U.S. healthcare market. Since 2016, we have provided Enterprise Ireland client companies with direct access to clinical experts across one of America’s largest health systems, resulting in meaningful outcomes including procurement contracts, clinical pilots and trials, and strategic investments from Northwell Ventures. We look forward to welcoming the next generation of Irish healthcare innovators and supporting their growth in the U.S. market.”

The organisations confirmed that the merger, while financial terms remain undisclosed, will establish what they describe as the largest clinical reporting network in the UK. The combined service is set to span major diagnostic subspecialties and expand capacity to manage both routine and urgent cases.

Medica currently delivers remote teleradiology reporting services to radiology departments across 55% of NHS Trusts. Its clinical focus areas include stroke imaging, cardiac, PET CT, and nuclear medicine, supporting hospitals with off-site specialist expertise.

Axon Diagnostics operates in digital pathology, working with NHS and private healthcare providers to manage caseloads and enable remote reporting workflows. Its cloud-based teleradiology and telepathology platform underpins these services, allowing clinicians to access and report cases remotely.

Through the integration of Axon’s platform and artificial intelligence (AI)-based workflow tools alongside clinical desktop technology from Axon’s sister company, MITIS Medica stated that the enlarged organisation will introduce more streamlined workflows. The aim, it said, is to enhance efficiency and cost effectiveness for clients, in line with the NHS’s long term priorities.

The announcement comes against the backdrop of the UK government’s 10-year plan for the NHS, unveiled in July 2025. In that plan, the UK’s Labour government highlighted the acceleration of AI deployment in hospitals to support clinical reporting in radiology and pathology. The strategy also emphasised remote monitoring to enable virtual care for patients at home.

Medica CEO Andrew Cannon commented: “Bringing Axon into Medica strengthens our position as the UK’s leading diagnostics provider. Clients will continue to receive the excellent service they rely on, now supported by greater capacity and advanced reporting technology.”

To finalise the merger, both companies said they are implementing a phased integration plan designed to bring together their systems, teams, and best practice protocols in a “structured and transparent” manner.

Axon CEO Rahul Mehta commented: “This merger combines our technology and agile approach with Medica’s scale and clinical excellence, meaning more patients will benefit from faster and smarter reporting.”

The transaction also unfolds amid workforce pressures in UK radiology. According to the Royal College of Radiologists (RCR), the country faces a 30% shortfall in clinical radiologists, a figure projected to increase to 40% by 2028 if no corrective measures are taken. In response to these constraints, teleradiology has increasingly served as a key stopgap solution, helping to ease clinician burnout while addressing rising caseloads.

The deal opens access to the European Union’s USD 572.3 billion pharmaceuticals and medical devices market, giving Indian companies preferential or zero-tariff entry, while EU firms benefit from India’s tariff reductions on imported medical equipment.

Together, India and the EU represent close to a quarter of global GDP and serve a combined population of nearly two billion people. Announcing the deal, European Commission President Ursula von der Leyen said, “We did it, we delivered the mother of all deals,” while Prime Minister Narendra Modi described the agreement as “historic”.

Under the India-EU Free Trade Agreement, India will reduce or eliminate customs duties on around 90% of medical and surgical equipment categories. Tariffs that currently reach as high as 27.5% will gradually fall to zero, easing the cost burden on imported European technologies.

The moves will likely reduce the price of purchasing these advanced imaging devices such as CT scanners, MRI machines and ultrasounds along with critical-care gear and high-end diagnostics. These items already constitute a major portion of imports into India of medical technology products, especially those used in tertiary and quaternary care.

Hospitals and diagnostic networks are likely to see improved access to advanced equipment, while patients may benefit from wider availability of cutting-edge technologies and reduced capital expenditure pressures across healthcare systems.

At the same time, Indian manufacturers gain improved access to European markets. Tariffs of up to 6.7% on medical instruments, devices, and related products are set to be removed across more than 99% of applicable lines, strengthening the export outlook for Indian MedTech companies.

Rajiv Nath, Forum Coordinator, AiMeD, said, “The India-EU FTA must ensure a level playing field for India’s medical device manufacturers. With fair regulatory alignment and safeguards against predatory imports (especially from 3rd countries), this agreement can unlock high-value collaboration, boost domestic manufacturing, and support India’s ambition to become a top-five global MedTech hub. The goal should be mutual growth anchored in quality, transparency, and patient safety under an MRA(mutual recognition agreement) based on common ISO standards. We look forward to reviewing the fine print and the follow-on cooperation discussions.”

Pavan Choudary, Chairman, Medical Technology Association of India (MTaI), added, “We congratulate India and the European Union on concluding this landmark agreement, which is expected to open a new chapter in healthcare cooperation – where success will be measured not only in GDP, but in lives improved and saved… Most importantly for patients, any eventual tariff reductions on medical devices should help improve affordability and access to advanced therapies, making this agreement a potential example of how ethical and equitable trade can reinforce health systems on both sides.”

Signals from the industry and policy makers suggest new openings for Indian-made medical devices, consumables, lenses, spectacles and in-vitro diagnostics produced at hubs located in Gujarat, Maharashtra, Karnataka and Andhra Pradesh. Lowering the costs for in-vitro diagnostics firms, zero tariff access will make them more competitive in Europe if companies adhere to stringent EU regulations.

The collaboration is expected to drive efforts in genomic diagnostics, with the eventual goal of improving patient outcomes and helping to guide future care. The organizations have also announced the launch of a prospective observational study called “Serial Molecular Profiling and Monitoring of Human Cancer.” Patients participating in the study will undergo sequencing at various time points during treatment to generate the longitudinal datasets that will be critical to the effort.

In addition to the initial research study, other work included in the collaboration involves assay validation, biomarker identification, biological modeling, real-world data analysis, and the development of artificial intelligence-powered predictive algorithms. The work is in addition to Tempus’ current role as a provider of next-generation sequencing testing services to NYU Langone Health.

“Through the integration of advanced genomic technologies and data science, we are deepening our understanding of cancer’s complexity and pioneering transformative approaches for patient monitoring and treatment,” said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus. “Our research is focused on generating actionable insights through better understanding of cancer response, resistance, and trajectory that will not only refine and enhance current assays, but also drive the creation of innovative diagnostic tools and algorithms that can empower clinicians to deliver truly individualized care to their patients.”

The Tempus-NYU Langone collaboration will be carried out within routine clinical care at the Perlmutter Cancer Center, allowing researchers to study serial molecular profiling in real-world settings.

“This strategic collaboration will further our ability to analyze cutting-edge serial molecular profiling technology in the routine care of patients at the Perlmutter Cancer Center at NYU Langone Health,” said Shridar Ganesan, MD, PhD, Director of the Center for Molecular Oncology at Perlmutter Cancer Center. “This approach will enable us to better understand the biology of individual cancers, inform our ability to implement and develop targeted therapies, and assess response and emerging resistance.”